Is Alkem Lab overvalued or undervalued?

As of 7 July 2025, Alkem Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently deemed undervalued, with a PE ratio of 26.86, a Price to Book Value of 4.85, and an EV to EBITDA ratio of 22.72. These ratios suggest that Alkem Lab is positioned favorably compared to its peers, particularly when compared to Sun Pharma, which has a significantly higher PE ratio of 35.25, and Divi's Lab, which is rated very expensive with an EV to EBITDA of 60.34. In the context of its industry, Alkem Lab's ROCE stands at 19.77% and ROE at 18.07%, reinforcing its operational efficiency and profitability relative to competitors. While the stock has underperformed the Sensex year-to-date with a return of -13.59% compared to the Sensex's 6.79%, the overall valuation metrics suggest that the stock presents a compelling investment opportunity at its current price of 4865.30.